Related Experiment Video
Updated: Jun 20, 2026
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
Bryan A Faller1, Barbara Burtness
1Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Abstract:
Pancreatic adenocarcinoma is a common malignancy that remains refractory to available therapies. Gemcitabine has long been the standard, first-line agent in advanced disease. The epidermal growth factor receptor (EGFR) is a commonly expressed target in pancreatic cancer that is involved in tumor proliferation, metastasis, and induction of angiogenesis. The addition of the EGFR inhibitor erlotinib to gemcitabine has recently been demonstrated to provide a small, yet statistically significant, survival benefit in advanced disease. This has prompted further research into the applications of EGFR-targeted therapy in pancreatic cancer, albeit with disappointing results. Resistance to these therapies seems highly prevalent and has been implicated in their limited efficacy. The development of rash is associated with treatment efficacy and suggests that predictive factors may one day be identified to guide appropriate patient selection for these agents. Preclinical research has shown promise that resistance to EGFR-targeted therapies can be overcome through a variety of approaches. Application of this research in clinical trials may ultimately yield an unquestioned role for EGFR-targeted therapy in the management of this disease.
Insights
Pancreatic cancer remains difficult to treat. While epidermal growth factor receptor (EGFR) inhibitors like erlotinib offer a small survival benefit with gemcitabine, resistance limits their effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Pancreatic adenocarcinoma is a challenging malignancy with limited therapeutic options.
- Gemcitabine is the current first-line treatment for advanced pancreatic cancer.
- Epidermal growth factor receptor (EGFR) is a key target in pancreatic cancer, influencing proliferation, metastasis, and angiogenesis.
Purpose of the Study:
- To review the current applications and limitations of EGFR-targeted therapy in pancreatic cancer.
- To explore the mechanisms of resistance to EGFR inhibitors.
- To discuss potential strategies to overcome resistance and improve patient selection.
Main Methods:
- Review of preclinical and clinical studies on EGFR inhibitors in pancreatic cancer.
- Analysis of factors associated with treatment efficacy, such as rash development.
- Exploration of emerging therapeutic approaches to overcome resistance.
Main Results:
- The combination of gemcitabine and erlotinib provides a modest survival benefit in advanced pancreatic cancer.
- Resistance to EGFR inhibitors is a significant challenge, limiting their efficacy.
- Rash development correlates with treatment effectiveness, suggesting potential predictive biomarkers.
Conclusions:
- EGFR-targeted therapy shows promise but faces significant resistance in pancreatic cancer.
- Further research is needed to identify predictive factors for patient selection.
- Overcoming resistance through novel strategies may establish a definitive role for EGFR inhibitors in pancreatic cancer management.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...